论文部分内容阅读
在欧洲,抗抑郁症药物正在对抗日益攀升的忧郁症和焦虑症发病率方面发挥越来越重要的作用。此外,人们亦在研究这些药物对治疗中枢神经系统(CNS)紊乱疾病的效果,从而增强了即将饱和的抗抑郁症药物市场的发展潜力。 Frost&Sullivan发现,2005年欧洲的抗抑郁症药物市场取得的营业收入为47亿美元,预计到2012年,这一数字将下降至45亿美元。 Frost&Sullivan调查分析师Sumanth Kambham-mettu博士对此指出,尽管营业收入可能有所下降,
In Europe, antidepressants are playing an increasingly important role in fighting the rising morbidities of depression and anxiety. In addition, the efficacy of these drugs in the treatment of disorders of the central nervous system (CNS) is also under study to enhance the potential of the market for anti-depression drugs to be saturated. Frost & Sullivan found that revenues from the anti-depression drug market in Europe were $ 4.7 billion in 2005 and that number is expected to drop to $ 4.5 billion by 2012. Frost & Sullivan research analyst Sumanth Kambham-mettu Dr. pointed out that although operating income may decline,